Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Deep Vein Thrombosis and Pulmonary Embolism: Clinical Treatment and Management
share announcement

Deep Vein Thrombosis and Pulmonary Embolism: Clinical Treatment and Management

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: 31 May 2024 | Viewed by 1604

Special Issue Editor

Dr. Pablo Demelo-Rodríguez

E-Mail Website
Guest Editor
Venous Thromboembolism Unit, Internal Medicine, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain
Interests: internal medicine; deep vein thrombosis; pulmonary embolism; cerebral venous thrombosis; venous thromboembolism; anticoagulation therapy

Special Issue Information

Dear Colleagues,

Deep vein thrombosis (DVT) and pulmonary embolism (PE) continue to be significant medical challenges, with increasing implications in terms of hospitalizations and morbidity. These conditions affect a substantial number of patients worldwide, and their consequences can be devastating if not adequately addressed. In this context, our Special Issue focuses on providing an updated and comprehensive insight into the clinical management and treatment of DVT and PE.

We invite contributions that address a wide range of topics, including the management of DVT, the use of systemic thrombolytic therapies, catheter-directed pulmonary reperfusion, mechanical thrombectomy for DVT, surgical embolectomy and extracorporeal embolectomy. We also explore bleeding risk assessment and management, right ventricular function, outpatient treatment of low-risk PE and/or DVT, and long-term management, encompassing anticoagulation, screening and the treatment of complications. Furthermore, we delve into the relationship between venous thrombosis and cancer, as well as complications associated with COVID-19-related venous thrombosis.

This Special Issue represents a compendium of cutting-edge research and reviews that will provide clinicians with a solid foundation to enhance our understanding of DVT and PE, and improve patient care.

We eagerly await your contributions!

Dr. Pablo Demelo-Rodríguez
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pulmonary embolism
  • thrombophilia
  • deep vein thrombosis
  • venous thromboembolism
  • anticoagulation therapy
  • thrombectomy
  • bleeding
  • cancer-associated thrombosis

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 2963 KiB  
Article
Thrombosis and Bleeding Risk Scores Are Strongly Associated with Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study
by Kunapa Iam-Arunthai, Supat Chamnanchanunt, Pravinwan Thungthong, Poj Intalapaporn, Chajchawan Nakhahes, Tawatchai Suwanban and Ponlapat Rojnuckarin
J. Clin. Med. 2024, 13(5), 1437; https://doi.org/10.3390/jcm13051437 - 1 Mar 2024
Viewed by 610
Abstract
Background: Internationally established guidelines mention pharmacological prophylaxis for all hospitalized COVID-19 patients. However, there are concerns regarding the efficacy and safety of anticoagulants. This study investigated the associations between thrombosis/bleeding risk scores and clinical outcomes. Methods: We conducted a retrospective review of adult [...] Read more.
Background: Internationally established guidelines mention pharmacological prophylaxis for all hospitalized COVID-19 patients. However, there are concerns regarding the efficacy and safety of anticoagulants. This study investigated the associations between thrombosis/bleeding risk scores and clinical outcomes. Methods: We conducted a retrospective review of adult patients admitted to two hospitals between 2021 and 2022. We analyzed clinical data, laboratory results, low molecular weight heparin (LMWH) use, thrombosis, bleeding, and 30-day survival. Results: Of the 160 patients, 69.4% were female, and the median age was 59 years. The rates of thrombotic complications and mortality were 12.5% and 36.3%, respectively. LMWH prophylaxis was administered to 73 of the patients (45.6%). The patients with high Padua prediction scores (PPS) and high IMPROVEVTE scores had a significantly higher risk of venous thromboembolism (VTE) compared to those with low scores (30.8% vs. 9.0%, p = 0.006 and 25.6% vs. 7.7%, p = 0.006). Similarly, elevated IMPROVEVTE and IMPROVEBRS scores were associated with increased mortality (hazard ratios of 7.49 and 6.27, respectively; p < 0.001). Interestingly, LMWH use was not associated with a decreased incidence of VTE when stratified by risk groups. Conclusions: this study suggests that COVID-19 patients with high thrombosis and bleeding risk scores have a higher mortality rate. Full article
(This article belongs to the Special Issue Deep Vein Thrombosis and Pulmonary Embolism: Clinical Treatment and Management)
►▼ Show Figures

Figure 1

11 pages, 714 KiB  
Article
Prognostic Significance of Heart Failure in Acute Pulmonary Embolism: A Comprehensive Assessment of 30-Day Outcomes
by Mariam Farid-Zahran, Manuel Méndez-Bailón, José María Pedrajas, Rubén Alonso-Beato, Francisco Galeano-Valle, Vanesa Sendín Martín, Javier Marco-Martínez and Pablo Demelo-Rodríguez
J. Clin. Med. 2024, 13(5), 1284; https://doi.org/10.3390/jcm13051284 - 24 Feb 2024
Viewed by 778
Abstract
Introduction: Patients with heart failure (HF) are known to have an increased risk of pulmonary embolism (PE), but there is limited evidence regarding the prognostic implications of HF in patients with acute PE and the relationship between PE prognosis and left ventricular ejection [...] Read more.
Introduction: Patients with heart failure (HF) are known to have an increased risk of pulmonary embolism (PE), but there is limited evidence regarding the prognostic implications of HF in patients with acute PE and the relationship between PE prognosis and left ventricular ejection fraction (LVEF). The primary objective of this study was the development of a composite outcome (mortality, major bleeding, and recurrence) within the first 30 days. The secondary objective was to identify the role of LVEF in predicting the development of early complications in patients with both HF and reduced LVEF. Material and Methods: A prospective study was conducted at two tertiary hospitals between January 2012 and December 2022 to assess differences among patients diagnosed with acute PE based on the presence or absence of a history of HF. Cox regression models were employed to assess the impact of HF and reduced LVEF on the composite outcome at 30 days. Results: Out of 1991 patients with acute symptomatic PE, 7.13% had a history of HF. Patients with HF were older and had more comorbidities. The HF group exhibited higher mortality (11.27% vs. 4.33%, p < 0.001) and a higher incidence of major bleeding (9.86% vs. 4.54%, p = 0.005). In the multivariate analysis, HF was an independent risk factor for the development of the composite outcome (HR 1.93; 95% CI 1.35–2.76). Reduced LVEF was independently associated with a higher risk of major bleeding (HR 3.44; 95% CI 1.34–8.81). Conclusion: In patients with acute pulmonary embolism, heart failure is independently associated with a higher risk of early complications. Additionally, heart failure with reduced LVEF is an independent risk factor for major bleeding. Full article
(This article belongs to the Special Issue Deep Vein Thrombosis and Pulmonary Embolism: Clinical Treatment and Management)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop